Dr Nizar Tannir describes data presented at ASCO 2022 from EVEREST investigating everolimus vs placebo for patients with high-risk disease.
Nizar Tannir, MD: This is a summary of the results of the TKIs [tyrosine kinase inhibitors]. You touched on it, Scott. All the trials with a targeted agent were negative except the one that you pointed out: S-TRAC, which led to the approval of sunitinib. ASSURE is the cooperative group study. PROTECT was with pazopanib. ASSURE was sorafenib vs sunitinib vs placebo. ATLAS was axitinib vs placebo. The SORCE trial was 2 doses of sorafenib vs placebo. Then we’ll talk a little about EVEREST, the latest study that was presented at ASCO [American Society of Clinical Oncology annual meeting] 2022. I put it in red because it’s a negative study in my opinion, although it was teetering on—you can see the upper bound of it, 95% confidence interval being 1. But the hazard ratio is only 0.85. I’d like to get your thoughts on this. Let’s go through the data from KEYNOTE-564.
Here is [the phase 3 EVEREST study] presented by Chris Ryan, [MD,] at ASCO [in June]. It was 1 year of everolimus vs placebo. Fifty-five percent of the recruited patients had very high risk, defined here as pT3a, grade 3 or 4, or pT3b-c or T4, any T, any grade but node positive vs the intermediate-high risk. They used relapse-free survival and not disease-free survival [DFS], like most of these adjuvant trials. There was a 63% improvement in 6-year relapse-free survival. The overall hazard ratio was 0.85, which didn’t meet the prespecified P value. We’ll see what the FDA will say, but I don’t think this is going to be a factor in the adjuvant setting. Especially now that we have other trials with combinations of immune checkpoint inhibitors coming out. I’ll go through those slides to show all the adjuvant trials in the IO [immunotherapy] space.
These are the studies of adjuvant IO in RCC [renal cell carcinoma]. We’ll talk about KEYNOTE-564 in detail. We’re awaiting the results of IMmotion010, CheckMate-914, and RAMPART. There was a statement that PROSPER RCC was negative. The primary end point for most of these was DFS. For PROSPER RCC, it was event-free survival. PROSPER RCC was a little different from the others because it isn’t strictly an adjuvant IO therapy because patients had a biopsy with the primary tumor still in situ, started on nivolumab when the primary was still in place, then had the nephrectomy, and then received further adjuvant nivolumab. The RAMPART trial, which would be the latest to read out in a couple of years, is a triplet similar to CheckMate-914, which is a triplet of dual checkpoint blockade vs monotherapy with anti–PD-1 vs placebo. RAMPART has observation rather than placebo, which was the control arm in CheckMate-914.
Transcript edited for clarity.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More